Placeholder Banner

BIO Comments on FDA Draft Guidance on Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings

December 17, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings, which FDA says is intended to assist sponsors of drug and biological products for rare diseases in planning and conducting more efficient and productive pre-investigational new drug application (pre-IND) meetings.

BIO applauds the FDA’s initiative to advance drug development and review for therapies to treat rare diseases. It’s estimated there are 7,000 identified rare diseases, but only 5% have an approved therapy. This guidance provides important information to drug developers to make the drug development process more consistent, transparent, and efficient. BIO provided general comments and line edits.

Download Full Comments Below
BIO Letter Rare Diseases Early Drug Development And The Role Of PreIND Meetings FDA–2018-D-3268
Read full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…